SCHEMBL19639779

SCHEMBL19639779

CCOC(=O)CC(=O)N(c1cccc(C(F)(F)F)c1)N(C)C(=O)c1nccn1-c1ccc(C#N)cc1

nearest known ligand 0.45

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ELANE P08246 19/20 0.45
CYP2C9 P11712 2/20 0.40
CYP3A4 P08684 2/20 0.39
RORC P51449 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19688776 0.93 ELANE (0.44) ELANECYP2C9CYP3A4RORC
SCHEMBL19639771 0.88 ELANE (0.40) ELANECYP2C9CYP3A4RORC
SCHEMBL19640140 0.85 ELANE (0.43) ELANECYP2C9CYP3A4RORC
SCHEMBL19639774 0.85 ELANE (0.39) ELANECYP2C9CYP3A4RORC
SCHEMBL19639815 0.80 RORC (0.41) ELANECYP2C9CYP3A4RORC
SCHEMBL19639785 0.79 ELANE (0.41) ELANECYP2C9CYP3A4RORC
SCHEMBL19656242 0.78 ELANE (0.43) ELANECYP2C9CYP3A4RORC
SCHEMBL19651234 0.78 ELANE (0.39) ELANECYP2C9CYP3A4RORC
SCHEMBL19639813 0.76 AURKA (0.42) ELANE
SCHEMBL19639758 0.75 ALOX15 (0.44) CYP2C9CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10172830-B2 Pyrazolone compounds having human neutrophil elastase inhibitory properties CHIESI FARMACEUTICI S.P.A. (IT) 2019-01-08 US disclosed
US-10172830-B2 Pyrazolone compounds having human neutrophil elastase inhibitory properties CHIESI FARMACEUTICI S.P.A. (IT) 2019-01-08 US disclosed
WO-2017207433-A9 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF A DISEASE IN WHICH HNE IS IMPLICATED CHIESI FARMACEUTICI S.P.A. (IT) 2018-03-01 WO disclosed
US-9862706-B2 Compounds CHIESI FARMACEUTICI S.P.A. (IT) 2018-01-09 US disclosed
US-9862706-B2 Compounds CHIESI FARMACEUTICI S.P.A. (IT) 2018-01-09 US disclosed
WO-2017207433-A1 HETETOCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF A DISEASE IN WHICH HNE IS IMPLICATED CHIESI FARMACEUTICI S.P.A. (IT) 2017-12-07 WO disclosed
US-20170340611-A1 NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. (IT) 2017-11-30 US disclosed
US-20170340611-A1 NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. (IT) 2017-11-30 US disclosed
US-20170342056-A1 NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. (IT) 2017-11-30 US disclosed
US-20170342056-A1 NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. (IT) 2017-11-30 US disclosed
US-20170340611-A1 NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. (IT) 2017-11-30 US disclosed
US-20170342056-A1 NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. (IT) 2017-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170340611-A1 NOVEL COMPOUNDS SERPINB1, ELANE, MPO ELANE 2/4885CYP2C9 3005/4885CYP3A4 1599/4885
US-20170342056-A1 NOVEL COMPOUNDS SERPINB1, ELANE, MPO ELANE 2/4885CYP2C9 2925/4885CYP3A4 1594/4885
US-10172830-B2 Pyrazolone compounds having human neutrophil elastase inhibitory properties SERPINB1, ELANE, EPX ELANE 2/4885CYP2C9 2241/4885CYP3A4 1162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.